公开(公告)号：US20200056176A1

公开(公告)日：2020-02-20

申请号：US16424100

申请日：2019-05-28

申请人： Ionis Pharmaceuticals, Inc.

发明人： Adam Mullick ,  Rosanne M. Crooke ,  Mark J. Graham ,  Kenneth W. Dobie ,  Thomas A. Bell, III ,  Richard Lee

IPC分类号： C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  A61K31/7088

摘要： Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.

公开(公告)号：US20180142244A1

公开(公告)日：2018-05-24

申请号：US15870306

申请日：2018-01-12

申请人： Ionis Pharmaceuticals, Inc.

发明人： Rosanne M. Crooke ,  Mark J. Graham ,  Richard Lee ,  Kenneth W. Dobie

IPC分类号： C12N15/113 ,  G01N33/50 ,  C12Q1/6883

CPC分类号： C12N15/113 ,  C12N15/1136 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2320/30 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5023 ,  C12N2310/3521

摘要： Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.

公开(公告)号：US10364433B2

公开(公告)日：2019-07-30

申请号：US15526471

申请日：2015-11-13

申请人： The Regents of the University of California ,  Ionis Pharmaceuticals, Inc.

发明人： Aldons J. Lusis ,  Brian Parks ,  Richard Lee

IPC分类号： C12N15/11 ,  C12N15/113 ,  C12N9/10 ,  A61K31/397 ,  A61K31/713 ,  A61K45/06

摘要： Provided herein are methods, compounds, and compositions for reducing expression of an AGPAT5 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids, insulin resistance and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a cardiometabolic disease, disorder or condition, or a physiological marker thereof, in an individual in need.

公开(公告)号：US20190077825A1

公开(公告)日：2019-03-14

申请号：US16085130

申请日：2017-03-16

申请人： Ionis Pharmaceuticals, Inc.

发明人： Richard Lee ,  Jeffrey R. Crosby

IPC分类号： C07H21/02 ,  A61P9/10 ,  A61P25/28 ,  A61P11/06 ,  A61P3/10 ,  A61P29/00 ,  C12N15/113

摘要： Provided herein are methods, compounds, and compositions for reducing expression of KEAP1 in animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate oxidative stress or a disease, disorder or condition related to oxidative stress an animal in need. Diseases, disorders or conditions related to oxidative stress include NASH, NAFLD, asthma and insulin resistance.

公开(公告)号：US12115225B2

公开(公告)日：2024-10-15

申请号：US17231409

申请日：2021-04-15

申请人： AstraZeneca AB ,  Ionis Pharmaceuticals, Inc.

发明人： Brett P. Monia ,  Thazha P. Prakash ,  Garth A. Kinberger ,  Richard Lee ,  Punit P. Seth ,  Shalini Andersson ,  Eva Carina Ämmälä ,  Daniel Laurent Knerr ,  Maria Astrid Ölwegård-Halvarsson ,  Eric Valeur ,  William John Drury, III

IPC分类号： C07H21/04 ,  A61K31/7125 ,  A61K31/713 ,  A61K38/17 ,  A61K47/54 ,  A61K47/64 ,  A61K47/65 ,  C12N15/11 ,  A61P35/00

CPC分类号： A61K47/6425 ,  A61K31/7125 ,  A61K31/713 ,  A61K38/1796 ,  A61K47/549 ,  A61K47/65 ,  C12N15/111 ,  A61P35/00 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/3513 ,  C12N2310/3521 ,  C12N2310/3525 ,  C12N2310/3533 ,  C12N2320/32 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2310/321 ,  C12N2310/3525 ,  C12N2310/322 ,  C12N2310/3533

摘要： The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.

公开(公告)号：US11225664B2

公开(公告)日：2022-01-18

申请号：US16722043

申请日：2019-12-20

申请人： Ionis Pharmaceuticals, Inc.

发明人： Rosanne M. Crooke ,  Mark J. Graham ,  Richard Lee ,  Kenneth W. Dobie

IPC分类号： C12N15/113 ,  G01N33/50 ,  C12Q1/6883

摘要： Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.

公开(公告)号：US20210346509A1

公开(公告)日：2021-11-11

申请号：US17231409

申请日：2021-04-15

申请人： AstraZeneca AB ,  Ionis Pharmaceuticals, Inc.

发明人： Brett P. Monia ,  Thazha P. Prakash ,  Garth A. KINBERGER ,  Richard Lee ,  Punit P. Seth ,  Shalini Andersson ,  Eva Carina Ämmälä ,  Daniel Laurent Knerr ,  Maria Astrid Ölwegård-Halvarsson ,  Eric Valeur ,  William John Drury, III

IPC分类号： A61K47/64 ,  A61K31/7125 ,  A61K31/713 ,  C12N15/11 ,  A61K47/65 ,  A61K47/54 ,  A61K38/17

摘要： The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.

公开(公告)号：US10961271B2

公开(公告)日：2021-03-30

申请号：US16085130

申请日：2017-03-16

申请人： Ionis Pharmaceuticals, Inc.

发明人： Richard Lee ,  Jeffrey R. Crosby

IPC分类号： C07H21/02 ,  A61K31/7125 ,  A61K31/7115 ,  A61K31/713 ,  A61K31/712 ,  C07H21/04 ,  C12N15/113 ,  A61P9/10 ,  A61P25/28 ,  A61P11/06 ,  A61P3/10 ,  A61P29/00

摘要： Provided herein are methods, compounds, and compositions for reducing expression of KEAP1 in animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate oxidative stress or a disease, disorder or condition related to oxidative stress an animal in need. Diseases, disorders or conditions related to oxidative stress include NASH, NAFLD, asthma and insulin resistance.

公开(公告)号：US20210052631A1

公开(公告)日：2021-02-25

申请号：US15761769

申请日：2016-09-26

申请人： Ionis Pharmaceuticals, Inc.

发明人： Thazha P. Prakash ,  Richard Lee ,  Punit P. Seth ,  Eric E. Swayze ,  Frank Rigo ,  Michael Oestergaard

IPC分类号： A61K31/7125 ,  A61K9/00

摘要： Provided herein are oligomeric compounds comprising a modified oligonucleotide and a conjugate group for modulating the amount or activity of a target nucleic acid in extra hepatic tissues and extra hepatic cells. Also provided herein are methods of modulating the amount or activity of an extra-hepatic nucleic acid target in a cell comprising contacting the cell with the oligomeric compound or antisense compound.

公开(公告)号：US20190134214A1

公开(公告)日：2019-05-09

申请号：US16098971

申请日：2017-05-04

申请人： AstraZeneca AB ,  Ionis Pharmaceuticals, Inc.

发明人： Brett P. Monia ,  Thazha P. Prakash ,  Garth A. KINBERGER ,  Richard Lee ,  Punit P. Seth ,  Shalini Andersson ,  Eva Carina Ämmälä ,  Daniel Laurent Knerr ,  Maria Astrid Ölwegård-Halvarsson ,  Eric Valeur ,  William John Drury III

IPC分类号： A61K47/64 ,  A61K31/713 ,  A61K38/17 ,  A61K31/7125 ,  A61K47/54 ,  A61K47/65

摘要： The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.